Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Nissay Asset Management Corp Japan ADV

Nissay Asset Management Corp Japan ADV grew its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 24,125 shares of the biopharmaceutical company’s stock after acquiring an additional 847 shares during the period. Nissay Asset Management Corp Japan ADV’s holdings in Regeneron Pharmaceuticals were worth $17,187,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of REGN. OFI Invest Asset Management purchased a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth $28,000. Rakuten Securities Inc. lifted its position in shares of Regeneron Pharmaceuticals by 62.5% during the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 15 shares during the last quarter. Avalon Trust Co purchased a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth $36,000. Crowley Wealth Management Inc. purchased a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth $36,000. Finally, Private Wealth Management Group LLC raised its stake in Regeneron Pharmaceuticals by 260.0% during the 4th quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company’s stock worth $38,000 after acquiring an additional 39 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on REGN shares. Piper Sandler cut their price target on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating on the stock in a research note on Monday, January 27th. JPMorgan Chase & Co. cut their price target on shares of Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an “overweight” rating on the stock in a research note on Monday, March 31st. UBS Group cut their price target on shares of Regeneron Pharmaceuticals from $768.00 to $633.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 30th. TD Cowen dropped their price objective on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a research note on Tuesday, February 4th. Finally, Leerink Partnrs upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 5th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, nineteen have issued a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $890.60.

Regeneron Pharmaceuticals Trading Down 0.5%

Shares of NASDAQ:REGN opened at $571.36 on Thursday. The company has a market cap of $62.46 billion, a PE ratio of 14.93, a P/E/G ratio of 2.34 and a beta of 0.43. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The company’s 50-day moving average price is $605.64 and its 200 day moving average price is $689.30. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $520.50 and a fifty-two week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). The company had revenue of $3.03 billion for the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm’s quarterly revenue was down 3.7% on a year-over-year basis. During the same period in the previous year, the business posted $9.55 EPS. Sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th will be paid a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, May 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.62%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.96%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.